{"id":853629,"date":"2025-05-22T07:07:01","date_gmt":"2025-05-22T11:07:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/"},"modified":"2025-05-22T07:07:01","modified_gmt":"2025-05-22T11:07:01","slug":"unicycive-therapeutics-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"Unicycive Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LOS ALTOS, Calif., May  22, 2025  (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences.<\/p>\n<p align=\"justify\">Event:\u00a0 \u00a0Lytham Partners Spring 2025 Investor Conference <br \/>Type:\u00a0 \u00a0Fireside Chat<br \/>Date\/Time:\u00a0 \u00a0Thursday, May 29, 2025, at 12:30 p.m. ET<\/p>\n<p align=\"justify\">Event:\u00a0 \u00a0Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference<br \/>Type:\u00a0 \u00a0Corporate Presentation with Moderated Q&amp;A<br \/>Date\/Time:\u00a0 \u00a0Wednesday, June 4, 2025, at 1 p.m. ET<\/p>\n<p align=\"justify\">A link to the live and archived webcasts may be accessed on the Unicycive website under the Investors section: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K5q_smUP2OMJI0iNB-i4otZa0nnyuWcSfqCEVA0KB6aCpnShmoT7cniX2E_pGceNPUJUs2L_2CsiXmI1XtmV3uURYDoUaIOYjgdbVqejqi27JrPQE9GuBHqKMzByWLx_xrBCLrc8Htu3GAv2rU4Qqg==\" rel=\"nofollow\" target=\"_blank\">Events and Presentations<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Unicycive Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive\u2019s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=12cUnr0ue_xHi-q73atBZZjoQ16IGxtJ0Rkar4FD7vsdImt9sZNqDKd4dFgk_oNJyD1uYumSrDru829rmhwm2NsU6bbqQ4FOYsM2zlOODofMbjd45AIPIcZl5KeFkOqWQ58YTGYAeUMi5pT_hUyt_sw0CnBYvVC3RWLw5Z7XFV6eiEk53ROThmgn4UEMw1VSImDfqfnJlu1E8MOHecd2tK5twmG_FrWOnnCOel-e4xE=\" rel=\"nofollow\" target=\"_blank\">Unicycive.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JmZmvE3CrOhlqtvVLVVXhqdPPwSB13syFzsIdUDV7aM4PyK_NZxpT-EE1cq_pmaCN6Txi41QHRrgA3np0LzMXfTlSod58ZqF3Q5tQESmpeg_Ogq_m-Lp81m_DyT7pT17r16KQ0LKkMOvY-lG8w_L86tMItU91HatK9y2M2P4DTMnBm_GWA6wDbTfo8BXYggiUgwxNUJ7zk1eQS8_hy1l8YkmDubS-PHaKzj1Wi1iYgqjFWIu-_qZCLADv8SsZoBV\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2gXa8zI9xjMKofDVALf7u8A5oWOqDgiNyGp4Dq_R5KriML8oRnDOtm3unos9wrgp2HX7vTVfmuxM4ZhzUzO9nhOKl1yP8vgsmn4paEkjyX9jphhnrrc7XoUgKHNoxuSagE1-UVKE1rLRsVxE90fsKRml3FvSh6F7K4BY5xFmisN3NRMRwimsU4CQ48zYulB4n4gxEc86YcWWsIrtMDUnDg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Kevin Gardner<\/strong><br \/>\n        <br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4vLLc-4qTy07IXLhPQVE6FRzwX60TYKVXEpLbfpqMJ3NUZi14pf3ktktdSWSiWsaEH9ho-IdLXchEmpWh6GYfqOHwbuKsZjJsXJUy0IAy1LiATvH4_NAs0iU8m3deVBWAP6k2gYhXRbOHyLWrekpfzir1psMb9wigbWv_PEvaN3pvFEgJm-kTOqg7h-CNTODpGGdt_oCxUHatSkP8p0ZftONttE7qmfXPyzofLUsVEnnFKlD6fWLJfohOwX_hkrwER_LiFLWWPUDqcfLuDsuzFMWp1vFSKuChA4w0eV1o_NKOsXnI7LBTyQahhL_VP7w\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>\n        <strong>Rachel Visi<\/strong><br \/>\n        <br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bZmZC4Tn0ExEvuz-T1iIEavZJGKpn8rNHlT4aBUIgM15UQ0tf-zT6FTD3rQS6JVAp_5ZlPVFd4ZfPyXElIqKjrZx4tTMyuIMr5Huvqwa1ULOD1twR-T1oPzz9Bx7v6HvfjCIxk3x6Uws5aO-99uPnB0WH_JfdxyQVyMfAcrdt8FoDHTZp5y7HF0X6j9NsYWUIGUO7VwaqU3HtGMey6ncaqE3QzhLt-_GWrd-mJ8beGkA_XOzOYnTTHgmfDFD4VcrjIFFADYbiGkOWka2wan7HXmcqXnLz00oomDEpdCgq_c=\" rel=\"nofollow\" target=\"_blank\">redery@realchemistry.com<\/a><\/p>\n<p align=\"justify\">SOURCE: Unicycive Therapeutics, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjUzMTMyNjMtNWYwNi00NDZmLThmZTItODgyYTRhY2ZiYzE5LTEyMjIzMTYtMjAyNS0wNS0yMi1lbg==\/tiny\/Unicycive-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event:\u00a0 \u00a0Lytham Partners Spring 2025 Investor Conference Type:\u00a0 \u00a0Fireside ChatDate\/Time:\u00a0 \u00a0Thursday, May 29, 2025, at 12:30 p.m. ET Event:\u00a0 \u00a0Noble Capital Markets 2025 Emerging Growth Virtual Equity ConferenceType:\u00a0 \u00a0Corporate Presentation with Moderated Q&amp;ADate\/Time:\u00a0 \u00a0Wednesday, June 4, 2025, at 1 p.m. ET A link to the live and archived webcasts may be accessed on the Unicycive website under the Investors section: Events and Presentations. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Unicycive Therapeutics to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-853629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Unicycive Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Unicycive Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event:\u00a0 \u00a0Lytham Partners Spring 2025 Investor Conference Type:\u00a0 \u00a0Fireside ChatDate\/Time:\u00a0 \u00a0Thursday, May 29, 2025, at 12:30 p.m. ET Event:\u00a0 \u00a0Noble Capital Markets 2025 Emerging Growth Virtual Equity ConferenceType:\u00a0 \u00a0Corporate Presentation with Moderated Q&amp;ADate\/Time:\u00a0 \u00a0Wednesday, June 4, 2025, at 1 p.m. ET A link to the live and archived webcasts may be accessed on the Unicycive website under the Investors section: Events and Presentations. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead &hellip; Continue reading &quot;Unicycive Therapeutics to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-22T11:07:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Unicycive Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2025-05-22T11:07:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"name\":\"Unicycive Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=\",\"datePublished\":\"2025-05-22T11:07:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Unicycive Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Unicycive Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Unicycive Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event:\u00a0 \u00a0Lytham Partners Spring 2025 Investor Conference Type:\u00a0 \u00a0Fireside ChatDate\/Time:\u00a0 \u00a0Thursday, May 29, 2025, at 12:30 p.m. ET Event:\u00a0 \u00a0Noble Capital Markets 2025 Emerging Growth Virtual Equity ConferenceType:\u00a0 \u00a0Corporate Presentation with Moderated Q&amp;ADate\/Time:\u00a0 \u00a0Wednesday, June 4, 2025, at 1 p.m. ET A link to the live and archived webcasts may be accessed on the Unicycive website under the Investors section: Events and Presentations. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead &hellip; Continue reading \"Unicycive Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-22T11:07:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Unicycive Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2025-05-22T11:07:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/","name":"Unicycive Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=","datePublished":"2025-05-22T11:07:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1NjIzMiM2OTU1MjMzIzIyMTA3NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Unicycive Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/853629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=853629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/853629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=853629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=853629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=853629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}